Key points from this report:
- Buy Carl Zeiss Meditec. The stock is on the right side of a new base with a pivot of €140.5. We recommend accumulating shares in anticipation of a breakout.
- Business approaching pre-COVID levels. This is a reopening play. The APAC region is leading the way in the recovery with China and South Korea being key growth markets. Given the mass vaccinations expected this year, elective surgery volume is expected to improve.
- Leader in refractive laser surgery. Carl Zeiss has 25%+ market share in the refractive laser eye surgery market. The global market for refractive surgery is estimated to be $1B with a 6-7% CAGR. The company is growing by low-double digits, driven by its superior procedure SMILE.
- Total addressable market worth $12B. The company provides the most comprehensive diagnostic and surgical portfolio in eye care, ranging from routine diagnostic, retinal imaging, biometry to refractive laser surgery, surgical microscopy, and intraocular lenses. Surgical ophthalmology is the largest market at $8.5B, growing by mid-single digits.